Effect of rAd5-vector HIV-1 preventive vaccines on HIV-1 acquisition: A participant-level meta-analysis of randomized trials

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Huang, Yunda ^a   Follmann, Dean ^b   Nason, Martha ^b   Zhang, Lily ^a   Huang, Ying ^a   Mehrotra, Devan V ^c   Moodie, Zoe ^a   Metch, Barbara ^a   Janes, Holly ^a   Keefer, Michael C ^d   Churchyard, Gavin ^e   Robb, Merlin L ^f   Fast, Patricia E ^g   Duerr, Ann ^a   McElrath, M Juliana ^a   Corey, Lawrence ^a   Mascola, John R ^b   Graham, Barney S ^b   Sobieszczyk, Magdalena E ^h   Kublin, James G ^a   Robertson, Michael ^c   Hammer, Scott M ^h   Gray, Glenda E ⁱ   Buchbinder, Susan P ^j   Gilbert, Peter B ^a   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e AURUM INSTITUTE   (South Africa)

^f HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HVTN505 VACCINE; MRKAD5 VACCINE; UNCLASSIFIED DRUG; DNA VACCINE; GAG PROTEIN; NEF PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; POL PROTEIN; VIRUS ENVELOPE PROTEIN;

ARTICLE; CIRCUMCISION; COHORT ANALYSIS; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; VACCINATION; GENE VECTOR; GENETICS; HIV INFECTIONS; HUMAN ADENOVIRUS C; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPLAN MEIER METHOD; THERAPEUTIC USE; VIROLOGY;

ADENOVIRUSES, HUMAN; AIDS VACCINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, DNA;

EID: 84947740518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136626     Document Type: Article

References (31)

1. Choi Y, Chang J. Viral vectors for vaccine applications. Clinical and experimental vaccine research. 2013; 2(2): 97-105. doi: 10.7774/cevr.2013.2.2.97 PMID: 23858400
2. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653): 1881-93. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954
3. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11(7): 507-15. doi: 10.1016/S1473-3099(11)70098-6 PMID: 21570355
4. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369(22): 2083-92. doi: 10.1056/NEJMoa1310566 PMID: 24099601
5. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV- 1 DNA vaccine in Africa. PLoS One. 2010; 5(9): E12873. doi: 10.1371/journal.pone.0012873 PMID: 20877623
6. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis. 2010; 201(4): 600-7. doi: 10.1086/650299 PMID: 20078213
7. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011; 6(8): E21225. doi: 10.1371/journal.pone.0021225 PMID: 21857901
8. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012; 206(2): 258-66. doi: 10.1093/infdis/jis342 PMID: 22561365
9. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: Unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014; 14(5): 388-96. doi: 10.1016/S1473-3099(14)70020-9 PMID: 24560541
10. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: Rationale, conduct, and reporting. Bmj. 2010; 340: C221. doi: 10.1136/bmj.c221 PMID: 20139215
11. Fisher DJ, Copas AJ, Tierney JF, Parmar MK. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. Journal of clinical epidemiology. 2011; 64(9): 949-67. doi: 10.1016/j.jclinepi.2010.11. 016 PMID: 21411280
12. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. Biometrika. 1994; 81(3): 515-26.
13. Wu L, Gilbert PB. Flexible weighted log-rank tests optimal for detecting early and/or late survival differences. Biometrics. 2002; 58(4): 997-1004. PMID: 12495155
14. Hoenig JM, Heisey DM. The abuse of power: The pervasive fallacy of power calculations for data analysis. Am Stat. 2001; 55(1): 19-24.
15. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in medicine. 2002; 21(22): 3337-51. PMID: 12407676
16. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria2012.
17. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007; 25(20): 4085-92. PMID: 17391815
18. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis. 2006; 194(12): 1650-60. PMID: 17109336
19. Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, Gomez PL, et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr. 2007; 44(5): 601-5. PMID: 17325604
20. Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, et al. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. 2010.
21. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12): 1638-49. PMID: 17109335
22. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008; 46(11): 1769-81. doi: 10.1086/587993 PMID: 18433307
23. Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol. 2009; 16(9): 1285-92. doi: 10.1128/CVI.00144-09 PMID: 19605598
24. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses. 2009; 25(1): 103-14. doi: 10.1089/aid.2008.0212 PMID: 19108693
25. Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One. 2013; 8(4): E59340. doi: 10.1371/journal. pone.0059340 PMID: 23577062
26. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, et al. Safety and immunogenicity of a replication- defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054). PLoS One. 2010; 5(10): E13579. doi: 10.1371/journal.pone.0013579 PMID: 21048953
27. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, et al. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol. 2011; 187(6): 3391-401. doi: 10.4049/jimmunol.1101421 PMID: 21844392
28. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, et al. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: A randomized clinical trial. PLoS One. 2011; 6(9): E24517. doi: 10.1371/journal.pone.0024517 PMID: 21931737
29. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet. 2008; 372(9653): 1894-905. doi: 10.1016/S0140-6736(08)61592-5 PMID: 19012957
30. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012; 122(1): 359-67. doi: 10.1172/JCI60202 PMID: 22201684
31. Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, et al. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication- defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol. 2012; 86(4): 2239-50. doi: 10.1128/JVI.06175-11 PMID: 22156519